The malignant melanoma market has become increasingly crowded in recent years with novel treatments expanding therapy options for patients and segmenting the market according to BRAF mutational status. The introduction of immune checkpoint inhibitors such as Merck & ;s Keytruda and Bristol-Myers Squibb’s Opdivo has led to their domination of this market. The treatment algorithm will continue to evolve, with the entry of several agents into the underpenetrated and high opportunity resectable setting, the advent of triplet BRAF/MEK/immune checkpoint inhibitor combinations in the unresectable or metastatic setting, and the market entry of IDO-1 inhibitors in combination with PD-1 inhibitors. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.
Questions Answered:
How large are the clinically and commercially relevant drug-treatable malignant melanoma populations and how will drug-treatment rates change (if at all) over time?
What is the current state of treatment in malignant melanoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
What pipeline products are most promising, and what sales/uptake could they secure in the malignant melanoma market? What does the early phase pipeline look like?
What are the drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?